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ABSTRACT: The evaluation of new tuberculosis (TB) therapies
is limited by the paucity of biomarkers to monitor treatment
response. Previous work detected an uncharacterized urine
metabolite with a molecular mass of 874.3547 Da that showed
promise as a biomarker for successful TB treatment. Using mass
spectrometry combined with enzymatic digestions, the metabolite
was structurally characterized as a seryl-leucine core 1 O-
glycosylated peptide (SLC1G) of human origin. Examination of
SLC1G in urine revealed a significant abundance increase in
individuals with active TB versus their household contacts and
healthy controls. Moreover, differential decreases in SLC1G levels
were observed by week one in TB patients during successful treatment versus those that failed treatment. The SLC1G levels
were also associated with clinical parameters used to measure bacterial burden (GeneXpert) and inflammation (positron
emission tomography-computed tomography (PET-CT)). These results demonstrate the importance of metabolite
identification and provide strong evidence for applying SLC1G as a biomarker of TB treatment response.
KEYWORDS: tuberculosis, treatment response, urine metabolite, glycopeptide, core 1 oligosaccharide, mass spectrometry, PET-CT,
prognostic biomarker
Tuberculosis (TB) is the leading cause of mortalityworldwide due to an infectious agent, Mycobacterium
tuberculosis (Mtb).1 A contributing factor to the global burden
of TB is the continued emergence of drug resistant Mtb strains.
Efforts to combat such strains have led to new anti-TB
therapies and regimens.2 Nevertheless, clinical evaluations of
new drugs are protracted and typically include a six month
treatment regimen with patient follow-up for 12 to 18 months
to monitor for disease relapse. These parameters increase the
expense of clinical trials and impede the implementation of
new drugs for patient care.2 Thus, identification and validation
of biomarkers that provide an early surrogate end point for the
long-term outcome of TB treatment has emerged as a research
priority.
During the course of Mtb infection and treatment, metabolic
changes occur in the human host as well as the pathogen.3
Metabolomics provides a unique tool to capture changes in the
profile of small molecule metabolites during infection and
treatment. In fact, liquid chromatography−mass spectrometry
(LC-MS)-based metabolomics have successfully detected
metabolic alterations during the progression from Mtb
infection to active disease and during anti-TB therapy,
supporting the development of metabolite-based biosigna-
tures.4−6 However, many of the metabolites detected in
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untargeted metabolomics studies remain structurally unchar-
acterized or only putatively identified and require de novo
structural identification.7,8
Previously, 12 urine metabolites that significantly changed
during successful anti-TB treatment were reported. However,
five of these metabolites did not match with any compound in
available databases, and seven had putative, yet unconfirmed,
identifications.5 The structural characterization of one of these
metabolites as N-acetylisoputreanine has led to the discovery
that alterations in polyamine metabolism occur during TB and
response to treatment,8 an observation now confirmed by
others.9 A second unidentified metabolite designated as
molecular feature (MF) 874.3547, on the basis of its
monoisotopic mass of 874.3547 Da, decreased in abundance
early in the treatment of TB and remained at decreased levels
until the end of treatment. In this current study, we applied
liquid chromatography (LC) tandem mass spectrometry (MS/
MS) combined with enzymatic degradation and analyses of
synthetic products to elucidate the structure of MF 874.3547
as a seryl-leucine core 1 O-glycosylated peptide (SLC1G).
Evaluation of SLC1G in urine from patients with active
pulmonary TB (index cases) and their healthy household
contacts (HHC) confirmed that this novel urine metabolite is
significantly elevated in active TB. Assessment of SLC1G levels
in TB patients undergoing standard anti-TB therapy revealed
changes in metabolite abundances that are associated with
different clinical outcomes (treatment failure, stable long-term
cure, or recurrent TB) and measures of inflammation and
bacterial load.
■ RESULTS AND DISCUSSION
MS/MS Analyses of MF 874.3547 Reveal Glycopep-
tide Fragmentation Patterns. Initial structural information
pertaining to MF 874.3547 was obtained by LC-MS/MS
fragmentation at different collision energies, with the
consistency of the MF 874.3547 fragmentation pattern
confirmed using urine samples from six TB patients. MF
874.3547 also was present in commercial and healthy control
(HC) urine (Figure S1). A representative MS/MS spectrum of
the [M + H]+ adduct (m/z 875.3582) of MF 874.3547 from
one TB patient is shown in Figure 1A. Manual interrogation of
the MS/MS spectrum revealed diagnostic fragment ions for N-
acetylhexosamine (m/z 204.0856) and N-acetylneuraminic
acid (Neu5Ac) (m/z 292.1045), as well as neutral losses
corresponding to Neu5Ac (291.09 Da), hexose (162.05 Da),
and N-acetylhexosamine (203.07 Da) (Figure 1A). Impor-
tantly, the fragment ions m/z 584.2627, m/z 422.2120, and m/
z 219.1328 represented the sequential loss of Neu5Ac, hexose,
and N-acetylhexosamine from the parent ion (m/z 875.3582),
respectively. The difference between the parent ion m/z
875.3582 and the fragment ion m/z 657.2318 represented a
neutral loss of 218.1264 Da that corresponded to the fragment
ion m/z 219.1328 (Figure 1A). These data led to the
hypothesis that MF 874.3547 is a glycoconjugate containing
an oligosaccharide composed of N-acetylhexosamine, hexose,
and Neu5Ac (m/z 657.2318) attached to an unknown
structure with a mass of 218.1264 Da (m/z 219.1328).
Typically, biological glycoconjugates are glycolipids or
glycoproteins; thus, the m/z 219.1328 fragment ion likely
represented a lipid or peptide structure. This m/z value did not
Figure 1. MS/MS interrogation of MF 874.3547 leads to hypothesis of glycopeptide structure. Representative MS/MS spectrum of MF 874.3547
in TB patient urine obtained using collision energy of 20 V (A). Horizontal lines depict neutral losses within the MS/MS spectrum for Neu5Ac
(291.09 amu) in red, hexose (162.05 amu) in green, N-acetylhexosamine (203.07 amu) in blue, and the unknown dipeptide (218.13 amu) in black.
Diagnostic fragment ions for N-acetylhexosamine (m/z 204.0856) and Neu5Ac (m/z 292.1045) were present. (B) A hypothesized structure with
theoretical fragment ions matching those observed in the experimental MS/MS spectrum.
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Figure 2. Enzymatic deglycosylation and MS confirmation of core 1 glycosylation. MF 874.3547 untreated (A, C, E, G, I) and treated with α2-3,6,8
neuraminidase and O-glycosidase (B, D, F, H, J) were analyzed by LC-MS, and the spectra were evaluated by extracted ion chromatogram (EIC)
for intact glycopeptide (A and B), the glycopeptide minus Neu5Ac (C and D), the Hex−HexNAc disaccharide (E and F), Neu5Ac (G and H), and
the deglycosylated putative diamino acid S/TX (I and J). The * in panel C indicates a low level of the glycopeptide minus Neu5Ac (m/z 584.2661)
present in the undigested sample. Note the level of this product was considerably higher following digestion (G). In source fragmentation of
SLC1G yielded the m/z 584.2661 product (# in panel C) at the same retention time as the undigested glycopeptide.
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match any lipid moiety or fragments of glycolipids annotated
in existing databases,10 and the glycosylation pattern of N-
acetylhexosamine, hexose, and Neu5Ac was similar to that of
glycoproteins rather than glycolipids.11,12 Thus, the m/z
219.1328 fragment ion was hypothesized to represent a
peptide. Glycosylation of glycoproteins typically occurs on
asparagine (Asn) residues (N-linked), as well as serine (Ser) or
threonine (Thr) residues and to a lesser extent tyrosine (Tyr),
hydroxylysine, or hydroxyproline residues (O-linked).12−14 Six
amino acid combinations that included at least one of these
amino acids and possessed a predicted monoisotopic mass of
218.1311 Da were identified: Ser and leucine (Leu) or
isoleucine (Ile), or Thr and valine (Val). This indicated an O-
glycosylated peptide.
The most predominant form of protein O-glycosylation is a
Ser or Thr residue α linked to N-acetylgalactosamine
(GalNAc) followed by subsequent sugar moieties and
terminating with Neu5Ac.12,15 Using this information and
the fragment ion data (Figure 1A), we developed a
hypothesized structure for MF 874.3547 (Figure 1B). In silico
analysis of this hypothesized structure yielded the fragment
ions m/z 657.2354, 584.2668, 454.1561, 422.2140, 292.1032,
and 219.1346 that were observed in the experimental spectrum
(Figure 1A).
Confirmation of MF 874.3547 as Seryl-Leucine Core 1
O-Glycosylated Peptide (SLC1G). To confirm that the
proposed oligosaccharide structure terminated in Neu5Ac, MF
874.3547 was enriched from human urine by HPLC and
treated with neuraminidase enzymes.15 Two neuraminidases,
one with specificity for α2-3 terminal Neu5Ac and one with
broad specificity for α2-3, α2-6, or α2-8, were applied to MF
874.3547 and commercial standards with α2-3 or α2-6 linked
terminal Neu5Ac residues (Figures S2 and S3). LC-MS
analyses of the enzymatic digests demonstrated complete
Figure 3. Confirmation of seryl-leucine peptide and SLC1G structure. EIC for m/z 219.1328 in LC-MS spectra of α2-3,6,8 neuraminidase and O-
glycosidase treated MF 874.3547 (A) and seryl-leucine standard (C). MS/MS of m/z 219.1328 from α2-3,6,8 neuraminidase and O-glycosidase
treated MF 874.3547 (B) and the seryl-leucine standard (D). The confirmed structure of Neu5Acα2-3Galβ1-3GalNAcα1-O-SerLeu for MF
874.3547 (E).
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hydrolysis of MF 874.3547 with both enzymes. Note the
absence of the m/z 875.3582 product and emergence of new
products, m/z 310.1130 (Neu5Ac) and m/z 584.2661 (a
disaccharide linked dipeptide) in Figure S2. This revealed that
the terminal sugar was an α2-3 linked Neu5Ac, as the use of
commercial glycopeptide standards demonstrated a linkage
other than α2-3 could not be digested with the α2-3 specific
neuraminidase. Specifically, the α2-3 neuraminidase digested
products with an α2-3 linked Neu5Ac (Figure S3B,C) but not
a structure with an α2-6 linked Neu5Ac (Figure S3A).
The disaccharide moiety remaining after digestion with
neuraminidase was proposed to be a core 1 oligosaccharide
(Galβ1-3GalNAc-), a structure that can be capped with
Neu5Ac.12 To test this, MF 874.3547 was digested with
neuraminidase and an O-glycosidase possessing endo-α-N-
acetylgalactosaminidase activity and specificity for core 1 and
core 3 O-linked disaccharides.12,15 Treatment of commercial
standards with the O-glycosidase demonstrated activity
consistent with that expected, as this enzyme only digested a
commercial standard possessing the core 1 disaccharide
(Figure S3C). LC-MS analyses of enriched MF 874.3547
following neuraminidase and O-glycosidase treatment resulted
in detection of two ions belonging to a disaccharide (m/z
384.1500) and the putative dipeptide (m/z 219.1328), as well
as the products observed with the neuraminidase only digest
(Figure 2). These data confirmed that MF 874.3547 contained
either a core 1 or core 3 O-linked disaccharide with a terminal
α2-3 linked Neu5Ac. Since core 3 disaccharides are
represented by GlcNAcβ1-3GalNAc-, only a core 1 dis-
accharide was consistent with both the MS/MS spectrum of
MF 874.3547 (Figure 1A) and the neuraminidase and O-
glycosidase treatment data (Figure 2). Thus, the glycosyl
structure of MF 874.3547 was confirmed as Neu5Acα2-
3Galβ1-3GalNAc.
The structure of the dipeptide was determined by comparing
synthetic peptide standards to the retention time and MS/MS
spectrum for the m/z 219.1328 product resulting from the
neuraminidase and O-glycosidase digestion of MF 874.3547.
Only the seryl-leucine standard matched both the retention
time and MS/MS spectrum of the m/z 219.1328 product
(Figures 3 and S4). This confirmed that the entire structure of
MF 874.3547 was Neu5Acα2-3Galβ1-3GalNAcα1-O-SerLeu, a
SLC1G (Figure 3E).
Figure 4. SLC1G levels are associated with active TB and different treatment response outcomes. Log2 abundances of SLC1G in index TB patients,
as compared to TST− and TST+ HHCs of the KCHS (A) and active TB patients at their diagnostic time point and HCs of the Catalysis Study
(B). Log2-fold change in SLC1G levels over 24 weeks of treatment differed in cured (C) and recurrent (E) treatment outcome groups as compared
to the failed (D) treatment group. The dashed line indicates a log2-fold change of −2. Fold changes at each time point are based on SLC1G levels
at the Dx time point. The data are representative of index (n = 10), TST− (n = 14), and TST+ (n = 12) patients (A), 14 healthy controls and TB
patients (n = 36) (B), and cured (n = 15), failed (n = 8), and recurrent patients (n = 12) (C, D, E). One cured patient was not included in the
analysis for (C) due to a missing week 8 time point. Statistical significance was determined using a one-way ANOVA with Tukey’s multiple
comparison test (A), an unpaired two-tailed t test (B), and a repeated measures one-way ANOVA with Tukey’s multiple comparison test (C, D, E).
Error bars represent the 95% confidence interval from the mean (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001).
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Naturally occurring peptides are common in the urine of
healthy individuals and are mainly products of normal
proteolytic degradation that occurs in tissue or body fluids.
Altered levels of these peptides may correspond to changes in
protein level or protease activity and have been associated with
a variety of diseases such as diabetes, chronic kidney disease,
and rheumatoid arthritis, as well as aging.16−19 Although Mtb
produces O-linked glycoproteins, these products possess
oligosaccharides of mannose20 and not the core 1 oligosac-
charide structure defined for SLC1G. Additionally, as
demonstrated below, SLC1G was identified in urine of healthy
controls. Thus, we concluded that SLC1G results from the
proteolysis of a host glycoprotein.
The elucidation of MF 874.3547 as SLC1G provides a
premise for the structural characterization of additional
metabolites identified via untargeted metabolomics experi-
ments and supports the use of host metabolites as indicators of
infectious disease. This is not a new concept in TB as host
metabolites were being investigated as biomarkers in the
1950s.21 More recently, Rhee and colleagues9 revealed several
host urine metabolites that distinguished TB patients from
those with other pulmonary diseases. These metabolites
included sugars contained in the SLC1G structure.
Levels of SLC1G Are Increased in Patients with Active
TB Compared to HHC. To establish that increased levels of
SLC1G are associated with active TB, the relative abundance
of this glycopeptide in active index TB patients and HHCs was
evaluated with urine collected under the Kawempe Commun-
ity Health Study (KCHS).22 The HHC included both
tuberculin skin test (TST) negative (−) and positive (+)
individuals. SLC1G levels were significantly higher in the index
patients compared to that of HHC (index vs TST−, p =
0.0003; index vs TST+ , p = 0.0255) (Figure 4A). SLC1G was
moderately higher in the TST+ group as compared to the
TST− group of HHCs, but a significant difference (p =
0.2201) was not obtained (Figure 4A). Using samples from a
separate study, the Catalysis Study,23 a significant difference
between urine SLC1G levels in active TB patients at the time
of diagnosis and healthy controls was observed (Figure 4B). It
is noted that the relative abundance of the SLC1G in the TB
patients of the Catalysis Study was similar to that of the
SLC1G in the index patients of the KCHS. The increased level
of SLC1G in active TB as compared to healthy individuals
provides strong evidence that this metabolite is associated with
active disease and its initial discovery as a potential treatment
response biomarker via untargeted metabolomics5 was not due
to alteration of host metabolism by anti-TB drugs.
Changes in SLC1G Levels Correlate with Different
Treatment Response Outcomes. Our previous study that
detected SLC1G as a potential biomarker anti-TB treatment
did not evaluate whether changes in SLC1G levels during
treatment differed between individuals successfully treated
versus those that failed treatment.5 To demonstrate that
SLC1G levels could serve as a prognostic biomarker of
treatment success, the Catalysis study samples were utilized on
the basis of availability of longitudinal patient samples
corresponding to different treatment outcomes. We evaluated
urine samples from TB patients designated as clinically cured
(individuals that converted to sputum culture negative before
or at the end of the 24 week treatment and remained culture
negative during a two year follow-up) (n = 15), those
designated as treatment failures (individuals that remained
sputum culture positive at the end of the 24 week treatment)
(n = 8), and a group of patients designated as cured but that
developed recurrent disease within 18 months of successful
treatment (n = 12)23 (Table 2). The levels of SLC1G at each
time point in the cured and failed patient groups were
compared using one-way ANOVA with Tukey’s multiple
comparison test. This demonstrated that the only significant
difference in SLC1G levels between these two patient groups
was at the week 24 time point (p = 0.038).
However, a comparison of SLC1G levels at baseline
(diagnosis) versus treatment time points (1, 4, 8, and 24
weeks) demonstrated a decrease during the first week of
treatment in all patient groups; however, the decrease was only
significant for the cured and recurrent TB groups (p = 0.0010
and 0.0243, respectively) (Figure 4C−E). Likewise, SLC1G
levels at all subsequent time points of treatment (4, 8, and 24
weeks) in comparison to baseline levels differed significantly
for the cured and recurrent TB groups but not the treatment
failure group (Figure 4). The rapid decrease in urine levels of
SLC1G after the start of anti-TB therapy coincides with early
periods of treatment when the largest decrease in bacterial load
is observed.24
The cured patient group also yielded a mean log2-fold
change between baseline and the end of treatment (week 24)
that was significantly larger than the fold change at week 1 of
treatment (Figures 4 and S5A−C). The magnitude of change
in SLC1G levels at weeks 4, 8, and 24 in the failed treatment
group was less than in the other groups, with a mean log2-fold
change of around −1. The cured and recurrent TB groups, in
comparison, yielded mean log2-fold changes below −1 (weeks
4 and 8) or below −2 (week 24) (Figures 4 and S5A−C). The
lack of a significant decrease in SLC1G levels during the initial
intensive phase of therapy (first two months) could have been
related to a greatly increased number of missed treatments in
this patient group (Table 2). However, the vast majority of
missed treatments occurred in the continuation phase, with
only one patient having a greater number of missed treatments
during the intensive phase.
Overall, SLC1G levels behaved similarly in cured and
recurrent TB patients. This observation was not unexpected as
the recurrent TB patients were initially designated as cured at
the end of treatment (week 24) and developed recurrent TB
within one year of successfully completing treatment. Further,
it is unknown whether recurrent TB in this patient cohort was
due to relapse of treated infections or new infections.23 The
relapse of TB after the completion of anti-TB therapy is an
outcome measured during clinical trials and is an important
parameter for which biomarkers are needed.2 Additional
studies with longitudinal urine from true relapse patients are
required to accurately evaluate the potential value of SLC1G as
a biomarker of relapse.
SLC1G Levels Associate with Clinical Measurements
of Inflammation and Bacterial Burden. The measure-
ments of bacterial load by GeneXpert MTB/RIF and
inflammation by positron emission tomography-computed
tomography (PET-CT) imaging are used as indicators of
treatment efficacy and disease resolution in clinical studies of
anti-TB therapies.23,25−27 Thus, using the cured and failed
treatment groups of the Catalysis Study, we explored whether a
relationship existed between SLC1G levels and pulmonary
inflammation (PET-CT combined total glycolytic activity
(COM TGAI) score) or bacterial load (GeneXpert Ct
value) regardless of treatment outcome. Using linear mixed
models, a 2-fold increase in SLC1G levels was associated with
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an increase in the PET-CT COM TGAI score of 0.82 (95%
CI: 0.58−1.06) and a decrease in the GeneXpert MTB/RIF Ct
values of 3.2 (95% CI: 2.4−4.5). The COM TGAI provides a
single metric to indicate the total burden of lung lesions as
measured by PET-CT. To visualize the associations
determined using linear mixed models, the COM TGAI scores
or GeneXpert MTB/RIF Ct values for all patients and all time
points, regardless of treatment outcome, were grouped into
four quantiles and plotted against SLC1G log2 normalized
abundances (Figure 5A,B). A positive association occurred
between SLC1G levels and increased inflammation (higher
COM TGAI scores) (Figure 5A). Likewise, lower SLC1G
levels were observed in patients with lower bacterial burdens
(i.e., increased GeneXpert MTB/RIF Ct values) (Figure 5B).
These associations are also apparent in scatter plots of COM
TGAI scores or GeneXpert MTB/RIF Ct values versus SLC1G
log2 normalized abundances for all patients and all time points
(Figure S5D,E). The studies of Malherbe et al.23 revealed that,
within the cured patient population, only 16% had resolved
their tubercle lesions at the end of treatment. We observed
SLC1G levels were increased in the cured patients who
remained PET-CT scan positive (i.e., COM-TGAI scores
>400) at the end of treatment relative to those that were
deemed resolved (Figure 5C). However, this difference was
not significant (p = 0.1079).
Time to sputum culture conversion is another end point
applied in clinical studies of anti-TB drugs as a measure of
bacterial clearance.28 The SLC1G levels in cured patient
samples prior to being designated culture negative were
significantly higher (p = 0.0166) than the SLC1G levels in
those same patients following conversion to culture negative
(Figure 5D). These data establish strong evidence that SLC1G
levels were linked with bacterial load and lung pathology in the
population study and could be applied to monitor the
resolution of disease and infection during treatment.
Figure 5. SLC1G levels associate with clinical measurements of bacterial burden and inflammation. Box plot of SLC1G abundances versus quantile
grouped GeneXpert MTB/RIF Ct values (A) and COM TGAI scores (B) for all cured and failed patients at all time points. SLC1G abundances
trended to increase in cured patients when week 24 COM-TGAI scores indicate persistent inflammation, COM-TGAI scores >400 (C). SLC1G
abundances differed significantly in the cured patient population before and after TSCC (D). The data represent patients with COM TGAI > 400
(n = 6) and patients with COM TGAI < 400 (n = 10) (C) and cured patients (n = 13) (D). Three patients were not included in the analysis for
(D) due to missing time points before or after sputum culture conversion. Statistical significance was performed with an unpaired two-tailed t test
(C) and paired t test (D). Box-and-whiskers plots have lines at the 25th, 50th (median), and 75th percentiles, and the whiskers extend to 1.5 times
the interquartile range (A, B). Error bars represent the 95% confidence interval from the mean (C, D) (**, p < 0.01).
ACS Infectious Diseases Article
DOI: 10.1021/acsinfecdis.8b00241
ACS Infect. Dis. 2019, 5, 353−364
359
Plasma Protease C1 Inhibitor: A Potential Source of
SLC1G. To establish a potential origin of SLC1G, the UniProt
database was queried for documented glycosylated proteins,
resulting in a list of 4508 proteins. Nine proteins with O-
glycosylation of a Ser-Leu motif were identified. On the basis
of previous literature, seven of these proteins were determined
to have the glycan structure of SLC1G (Table S1). Whole
blood RNaseq data for the Catalysis Study TB patients29 were
interrogated to determine whether any of the levels of the
transcripts for these seven proteins followed the same trend as
that observed for SLC1G during treatment. The transcript
belonging to plasma protease C1 inhibitor (C1INH) decreased
approximately 4-fold during treatment, following a similar
trend to that of SLC1G (Table S1). One study has reported
changes in expression of C1INH transcripts during anti-TB
treatment that are similar to the changes we observed in urine
levels of SLC1G.36 Additionally, expression of C1INH
transcripts also increases in active TB and household contacts
that progress to active disease.34,35 On the basis of these
results, C1INH was highlighted as a plausible precursor
protein of the glycosylated dipeptide.
C1INH is an abundant circulating protease inhibitor that
regulates complement and coagulation cascades and increases
during inflammation.30 One of the O-glycosylation sites in
C1INH (Ser-42) possesses an O-linked oligosaccharide
matching that of SLC1G and is followed by a Leu residue.31
Other studies have detected C1INH peptides in human urine
but not peptides containing the SLC1G motif.32,33 In addition
to C1INH, other proteins possessing the SLC1G glycosylation
motif, but that are not annotated as such in the UniProt
database, could also be a source of the glycopeptide.
Specifically, a glycosylated peptide in the C-terminus of
fibrinogen alpha chain isoform 2 with the sequence GKPSLSP
contains the SLC1G motif. This larger glycopeptide has been
identified in urine of individuals with febrile, complicated
urinary tract infections.37 Increased levels of serum fibrinogen
and fibrinogen degradation products also are noted to be
associated with active TB.38−40 Although metabolomics
measures the cumulative outcome of metabolic processes,
changes in the level of small peptides will be influenced by
alterations in the production and turnover of transcripts and
proteins. This, along with the potential for multiple proteins
giving rise to the same peptide, elevates the complexity of
studies required to determine the molecular events that
influence alterations in the level of specific peptides. Thus,
further studies are required to determine whether abundance
changes in the SLC1G glycopeptide arise from one or more
proteins with this motif or changes in the activity of proteases
as has been described to occur during active TB.41,42
■ CONCLUSION
Host metabolic responses provide a means to measure disease
severity and patient health. Unfortunately, the implementation
of metabolic biomarkers is impeded by a lack of structural
identification of potential diagnostic or prognostic metabolites
identified via untargeted metabolomics, as well as a scarcity of
data associating host metabolites to pathogen load or
inflammation. The elucidation of a previously uncharacterized
seryl-leucine glycopeptide and measurement of this metabolite
in human urine demonstrated that SLC1G levels decreased in
association with a reduction of bacterial load and inflammation
in patients being treated for TB providing evidence for a
specific relationship. The magnitude of change in relative levels
of glycopeptide differed between patients that were cured
versus those that failed TB treatment, and this difference
occurred within the first 2 months of treatment. A limitation of
this study was the small number of samples utilized. Thus,
future efforts with larger cohorts are necessary to validate
SLC1G as a prognostic marker of treatment outcome. It is
noted that an absolute quantification of the SLC1G
concentration in urine also was not determined. This is part
of ongoing efforts to establish quantifiable assays to measure
the abundance change in SLC1G and other metabolites during
TB treatment. Nevertheless, the data presented provide a basis
for development of host metabolite biomarkers to track the
early treatment response of TB patients and underscore the
value of continuing to structurally elucidate endogenous
human metabolites.
■ METHODS
Study Population. A subset of samples from the DMID
08-0023/TB Trials Consortium NAA2m study conducted in
Uganda5 were used for structural elucidation of MF 874.3547.
Patient urine for metabolite quantification was obtained from
the TBRU Kawempe Community Health Study (KCHS)
conducted in Uganda (http://www.case.edu/affil/tbru/
research_dmid01005.html) and the Catalysis Study (Stellen-
bosch University Human Research Ethics Committee approval
number N10/01/013) conducted in Cape Town, South
Africa.23 The KCHS urine samples represented a subset of
two cohorts22 and consisted of 10 index cases of TB and 26
HHC that were TST− (n = 14) and TST+ (n = 12) and were
without HIV comorbidity (Table 1). None of the KCHS HHC
went on to develop TB. The Catalysis Study urine samples23
consisted of 14 HC and 35 TB patients with different
treatment outcomes: 8 failed treatment, 12 recurrences, and 15
cured (Table 2). All of the available failed and recurrent
patients were utilized; however, only a subset of the total cured
patient population was utilized to maintain similar sample
numbers in each patient group. A posthoc power analysis was
performed using the mean SLC1G abundance and standard
deviation observed in the HHC samples to ensure adequate
power (>80%) for the sample sizes chosen (http://clincalc.
com/stats/Power.aspx). All of the parent studies were
reviewed and approved by their respective institutional review
boards or ethics committees in South Africa, Uganda, and the
United States. All participants gave informed consent for study
participation and sample retention for future research use.
Urine Processing and Osmolality. Patient urine samples
(40 to 45 μL) from the KCHS and Catalysis Study were
diluted 1:3 in LC-MS grade water. To produce quality control
samples for LC-MS, aliquots (5 μL) of individual urine
samples from either KCHS or Catalysis Study were pooled and
Table 1. Patient Characteristics, Kawempe Community
Household Study (Uganda)









mean age, years (SD) 35 (11) 24 (16) 28 (10)
male, n (%) 1 (10%) 5 (36%) 6 (50%)
location Uganda Uganda Uganda
mean PPD induration, mm
(SD)
14 (6) 2 (3) 16 (1)
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prepared for LC-MS identical to the individual samples.
Diluted urine (20 μL) osmolality46 was measured by freezing
point depression using a Micro-Osmometer Model 210
(Advanced Instruments, Norwood, MA). The instrument
was calibrated using both 55 and 850 mOsm standards
(Advanced Instruments). The accuracy of the instrument was
verified with a Clintrol 290 standard (Advanced Instruments).
MF 874.3547 Isolation and Digestion. MF 874.3547
was isolated from human urine (Gemini Bio-Products, West
Sacramento, CA) using the LC conditions previously
described.5 Fractions of 0.25 mL were collected from 18
replicate LC runs. Fractions within ±1 min of the target
retention time for MF 874.3547 were analyzed by LC-MS for
the presence of MF 874.3547. Fractions containing the MF
874.3547 were dried by SpeedVac and stored at −20 °C. The
stored fractions were suspended in 70 μL of water before
analyses.
MF 874.3547 (9 μL) or standards (60 ng) of 4-nitrophenyl
O-(N-acetyl-α-neuraminosyl)-(2-6)-β-D-galactopyranosyl-(1-
4)-2-acetamido-2-deoxy-β-D-glucopyranoside (EN4614, Car-
bosynth Ltd., San Diego, CA), glycan-F58 (ULM-10078-CA,
Cambridge Isotope Laboratories, Inc., Tewksbury, MA), and
Sialo Anti-Proliferative Factor (GP131025, Sussex Research
Laboratories, Ottawa, ON) were treated with α2-3 neurami-
nidase S (PO743S), α2-3,6,8 neuraminidase (#P0720S, New
England Biolabs Inc., Ipswich, MA, USA), and O-glycosidase
(#P0733S, New England Biolabs Inc.). Specifically, enzymatic
digests were performed with α2-3,6,8 neuraminidase (0.05
units), α2-3 neuraminidase S (0.008 units), or O-glycosidase
(80 units) in 15 μL (final vol) of 1× GlycoBuffer 2 (#B3704,
New England Biolabs Inc.) for 1 h at 37 °C. Reactions were
stopped with 70% methanol (final concentration) and
incubated at −80 °C for 1 h. Precipitated material was
removed by centrifugation (18 000g). The methanol extracts
were collected, dried by SpeedVac, and resuspended in 20 μL
of water prior to LC-MS and LC-MS/MS analyses.
LC-MS and LC-MS/MS Analyses. LC was based on a
previously described method using either an Agilent 1200 or
1290 series high-performance LC system (Agilent Technolo-
gies, Palo Alto, CA, USA) with an Atlantis T3 reverse-phase
C18 3.5 μm column (2.1 × 150 mm; Waters Corp., Milford,
MA).5 Injections (5 μL) of each diluted urine sample, enriched
MF 875.3547, or standard were made.
MS analyses of Catalysis Study samples and MS/MS
analyses for MF 874.3547 and seryl-leucine structural
characterization were performed using an Agilent 6520
quadrupole time-of-flight (Q-TOF) instrument equipped
with an electrospray ionization source operated in positive
ionization mode. The operating conditions were: gas temper-
ature, 300 °C; drying gas, 8 L/min; nebulizer, 45 lb/in2;
capillary voltage, 2000 V; fragmentation energy, 120 V;
skimmer, 60 V; octapole RF setting, 750 V. Specified ions
were isolated for MS/MS fragmentation using a mass window
of 1.3 Da. Collision induced dissociation was performed with
collision energies of 5 to 40 V. Data were collected in the
profile and centroid modes at a scan rate of 1.2 spectra/s and a
scan range of m/z 100 to 1700 for MS and a scan rate of 2.0
spectra/s and a scan range of m/z 100 to 1700 for MS/MS
using the Agilent MassHunter Data Acquisition software.
MS analyses of KCHS samples, enriched MF 874.3547, and
Sialo Anti-Proliferative Factor glycopeptide were performed
using an Agilent 6230 time-of-flight (TOF) instrument with an
electrospray ionization source operated in positive ionization
mode. The operating conditions for the mass spectrometer
were: gas temperature, 300 °C; drying gas, 11 L/min;
nebulizer, 40 lb/in2; capillary voltage, 2000 V; fragmentation
energy, 120 V; skimmer, 60 V; octapole RF setting, 750 V.
MS analyses of Glycan F58 and 4-nitrophenyl O-(N-acetyl-
α-neuraminosyl)-(2-6)-β-D-galactopyranosyl-(1-4)-2-acetami-
do-2-deoxy-β-D-glucopyranoside were performed using an
Agilent 6224 TOF instrument with an electrospray ionization
source operated in negative ionization mode. The operating
conditions for the mass spectrometer were: gas temperature,
325 °C; drying gas, 7 L/min; nebulizer, 40 lb/in2; capillary
voltage, 3500 V; fragmentation energy, 160 V; skimmer, 60 V;
octapole RF setting, 750 V. Data were collected on TOF
instruments in the profile and centroid modes at a scan rate of
1.0 spectra/s and a scan range of m/z 100 to 1700.
All patient samples were randomly assigned to batches and
analyzed by LC-MS in random order to avoid a patient group
bias based on SLC1G stability.
Analyses of MS/MS Spectra and LC-MS Data. The MS/
MS spectra were manually interrogated against the METLIN
database, the Human Metabolome Database (HMDB), and
the NIST/EPA/NIH Mass Spectral Library.43−45 Theoretical
fragment ions of MF 874.3547 were obtained using an ACD/
MS Fragmenter (Advanced Chemistry Development, Inc.,
Toronto, ON).
The LC-MS peak area of MF 874.3547 was used as the
SLC1G abundance in individual samples. The LC-MS peak
area of MF 874.3547 was normalized to the osmolality of the
corresponding sample as this is described as the gold standard
for estimating urinary concentration.46 Normalized abundance
values were log2 transformed and used to interrogate
significant differences in SLC1G levels between patient groups
using statistical analyses in GraphPad Prism version 6.04 for
Windows (GraphPad Software, La Jolla, California, USA).
Linear mixed models were performed using R version 3.4.247
with the lme4 package and a random subject effect to account
for repeated measures.48 Data used for the linear mixed models
were from TB patients of the Catalysis Study and included
combined total glycolytic activity (COM TGAI) from PET-
CT measurements and GeneXpert MTB/RIF Ct values as the
response variable and the normalized log2 SLC1G abundance
value from the same patient as the independent variable. The
COM TGAI is an aggregate value consisting of the TGAI and
cavity volume and was calculated using the formula COM
TGAI = [metabolic lesion volume (PET) × mean metabolic
Table 2. Patient Characteristics, Catalysis Study (South
Africa)a












33 (9) 35 (10) 34 (15) 32 (12)
male, n (%) 9 (60%) 7 (58%) 5 (63%) 7 (54%)





7 (0−23) 7 (0−32) 43 (0−99)b NA
aNA, not applicable. bThe mean number of missed treatments in the
intensive phase (first two months) and continuation phase (two to six
months) of treatment were 8 and 35, respectively.
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lesion intensity (PET)] + [cavity volume (CT) × mean
metabolic lesion intensity (PET)]. PET-CT data are available
through the Catalysis Biomarker Consortium Data Repository
(https://codr.c-path.org/main/home.html).
Data Repositories. Whole blood RNaseq data for the
Catalysis Study was obtained from the NCBI GEO database,
accession GSE89403. LC-MS data of SLC1G in patient urine
and MS/MS data for SLC1G structural elucidation have been
deposited in Metabolomics Workbench, Study IDs: ST001104
and ST001069. The SLC1G structure has been deposited in
the PubChem database, Pub Chem CID: 134687025.
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